gemapharm limited

gemapharm limited Company Information

Share GEMAPHARM LIMITED
Live 
MatureMidHigh

Company Number

03597444

Industry

Wholesale of pharmaceutical goods

 

Directors

Andrew Lamb

Bernard Schack

View All

Shareholders

saville holdings ltd

a-f sarl

Group Structure

View All

Contact

Registered Address

10 saville court saville place, clifton, bristol, BS8 4EJ

gemapharm limited Estimated Valuation

£4.7m

Pomanda estimates the enterprise value of GEMAPHARM LIMITED at £4.7m based on a Turnover of £9.3m and 0.5x industry multiple (adjusted for size and gross margin).

gemapharm limited Estimated Valuation

£4m

Pomanda estimates the enterprise value of GEMAPHARM LIMITED at £4m based on an EBITDA of £821.6k and a 4.87x industry multiple (adjusted for size and gross margin).

gemapharm limited Estimated Valuation

£4.9m

Pomanda estimates the enterprise value of GEMAPHARM LIMITED at £4.9m based on Net Assets of £2.5m and 1.97x industry multiple (adjusted for liquidity).

Edit your figures and get a professional valuation report.

Gemapharm Limited Overview

Gemapharm Limited is a live company located in bristol, BS8 4EJ with a Companies House number of 03597444. It operates in the wholesale of pharmaceutical goods sector, SIC Code 46460. Founded in July 1998, it's largest shareholder is saville holdings ltd with a 90% stake. Gemapharm Limited is a mature, mid sized company, Pomanda has estimated its turnover at £9.3m with high growth in recent years.

View Sample
View Sample
View Sample

Upgrade for unlimited company reports & a free credit check

Gemapharm Limited Health Check

Pomanda's financial health check has awarded Gemapharm Limited a 5 rating. We use a traffic light system to show it exceeds the industry average on 5 measures and has 2 areas for improvement. Company Health Check FAQs

Health Check Image
Health Rating5out of 5
positive_score

5 Strong

positive_score

4 Regular

positive_score

2 Weak

size

Size

annual sales of £9.3m, make it smaller than the average company (£25m)

£9.3m - Gemapharm Limited

£25m - Industry AVG

growth

Growth

3 year (CAGR) sales growth of 25%, show it is growing at a faster rate (5.6%)

25% - Gemapharm Limited

5.6% - Industry AVG

production

Production

with a gross margin of 28.5%, this company has a comparable cost of product (28.5%)

28.5% - Gemapharm Limited

28.5% - Industry AVG

profitability

Profitability

an operating margin of 8.9% make it more profitable than the average company (4.2%)

8.9% - Gemapharm Limited

4.2% - Industry AVG

employees

Employees

with 2 employees, this is below the industry average (36)

2 - Gemapharm Limited

36 - Industry AVG

paystructure

Pay Structure

on an average salary of £80.6k, the company has an equivalent pay structure (£80.6k)

£80.6k - Gemapharm Limited

£80.6k - Industry AVG

efficiency

Efficiency

resulting in sales per employee of £4.6m, this is more efficient (£662.4k)

£4.6m - Gemapharm Limited

£662.4k - Industry AVG

debtordays

Debtor Days

it gets paid by customers after 69 days, this is near the average (58 days)

69 days - Gemapharm Limited

58 days - Industry AVG

creditordays

Creditor Days

its suppliers are paid after 84 days, this is slower than average (27 days)

84 days - Gemapharm Limited

27 days - Industry AVG

stockdays

Stock Days

There is insufficient data available for this Key Performance Indicator!

- - Gemapharm Limited

- - Industry AVG

cashbalance

Cash Balance

has cash to cover current liabilities for 44 weeks, this is more cash available to meet short term requirements (13 weeks)

44 weeks - Gemapharm Limited

13 weeks - Industry AVG

debtlevel

Debt Level

it has a ratio of liabilities to total assets of 54.1%, this is a similar level of debt than the average (50.3%)

54.1% - Gemapharm Limited

50.3% - Industry AVG

GEMAPHARM LIMITED financials

EXPORTms excel logo

Gemapharm Limited's latest turnover from June 2024 is estimated at £9.3 million and the company has net assets of £2.5 million. According to their latest financial statements, Gemapharm Limited has 2 employees and maintains cash reserves of £1.9 million as reported in the balance sheet.

Data source: Companies HousePomanda Estimates

Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020Jun 2019Jun 2018Jun 2017Jun 2016Jun 2015Jun 2014Jun 2013Jun 2012Jun 2011Jun 2010
Turnover9,261,4796,321,2697,782,7374,775,0672,503,6511,806,1811,596,703514,784151,265103,28681,872279,690295,612343,282352,702
Other Income Or Grants000000000000000
Cost Of Sales6,624,8734,626,2675,549,4753,630,9821,832,4501,330,2411,174,229379,490110,33174,92260,477210,354228,405264,861273,991
Gross Profit2,636,6061,695,0022,233,2621,144,085671,202475,940422,474135,29340,93428,36421,39569,33667,20778,42178,711
Admin Expenses1,814,9611,909,1251,950,029970,000550,679436,790399,12474,00545,98913,07522,26070,90974,28380,0426,456
Operating Profit821,645-214,123283,233174,085120,52339,15023,35061,288-5,05515,289-865-1,573-7,076-1,62172,255
Interest Payable000000000000000
Interest Receivable99,156109,233008893,5903,4871,044325154760000
Pre-Tax Profit920,801-104,889283,233174,085121,41242,74126,83762,332-4,73015,443-790-1,573-7,076-1,62172,255
Tax-230,2000-45,463-35,315-23,068-8,121-5,099-11,8430-3,0890000-20,231
Profit After Tax690,601-104,889237,770138,77098,34434,62021,73850,489-4,73012,354-790-1,573-7,076-1,62152,023
Dividends Paid000000000000000
Retained Profit690,601-104,889237,770138,77098,34434,62021,73850,489-4,73012,354-790-1,573-7,076-1,62152,023
Employee Costs161,284153,787208,280199,273187,454187,101184,56057,72447,34843,82943,83140,93342,24241,16338,788
Number Of Employees223333311111111
EBITDA*821,645-214,123283,233174,085120,52339,15023,35061,288-5,05515,289-865-1,573-7,076-1,62172,255

* Earnings Before Interest, Tax, Depreciation and Amortisation

Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020Jun 2019Jun 2018Jun 2017Jun 2016Jun 2015Jun 2014Jun 2013Jun 2012Jun 2011Jun 2010
Tangible Assets000000000000000
Intangible Assets000000000000000
Investments & Other7,6337,6338,2198,2197,6957,9818,1428,1428,082000000
Debtors (Due After 1 year)1,681,187752,37100209,9370000000000
Total Fixed Assets1,688,820760,0048,2198,219217,6327,9818,1428,1428,082000000
Stock & work in progress000000000000000
Trade Debtors1,761,1121,528,7013,400,5661,530,166280,233290,690248,480024,91224,47716,16842,93244,55651,69853,274
Group Debtors000000000000000
Misc Debtors000000055,5114,425000000
Cash1,929,3311,848,0262,521,3032,132,9271,478,504299,147658,276736,47898,69831,19630,2960000
misc current assets000000000000000
total current assets3,690,4433,376,7265,921,8693,663,0941,758,737589,837906,756791,990128,03655,67446,46342,93244,55651,69853,274
total assets5,379,2624,136,7315,930,0883,671,3131,976,369597,818914,897800,131136,11755,67446,46342,93244,55651,69853,274
Bank overdraft000000000000000
Bank loan000000000000000
Trade Creditors 1,530,600660,6292,390,977795,767584,890218,014195,611001,0664,3160000
Group/Directors Accounts000000000000000
other short term finances000000000000000
hp & lease commitments000000000000000
other current liabilities733,376869,687763,910502,676444,334223,072597,148699,73186,216000000
total current liabilities2,263,9761,530,3163,154,8871,298,4431,029,224441,087792,760699,73186,2161,0664,3160000
loans000000000000000
hp & lease commitments000000000000000
Accruals and Deferred Income000000000000000
other liabilities648,438813,646876,178711,617692,1150000000000
provisions000000000000000
total long term liabilities648,439813,646876,179711,617692,1160000000000
total liabilities2,912,4152,343,9624,031,0662,010,0601,721,340441,087792,760699,73186,2161,0664,3160000
net assets2,466,8481,792,7681,899,0221,661,252255,029156,731122,138100,40049,90154,60842,14742,93244,55651,69853,274
total shareholders funds2,466,8481,792,7681,899,0221,661,252255,029156,731122,138100,40049,90154,60842,14742,93244,55651,69853,274
Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020Jun 2019Jun 2018Jun 2017Jun 2016Jun 2015Jun 2014Jun 2013Jun 2012Jun 2011Jun 2010
Operating Activities
Operating Profit821,645-214,123283,233174,085120,52339,15023,35061,288-5,05515,289-865-1,573-7,076-1,62172,255
Depreciation000000000000000
Amortisation000000000000000
Tax-230,2000-45,463-35,315-23,068-8,121-5,099-11,8430-3,0890000-20,231
Stock000000000000000
Debtors1,161,227-1,119,4941,870,3991,039,996199,48042,210192,96926,1744,8608,310-26,765-1,623-7,143-1,57653,274
Creditors869,971-1,730,3481,595,210210,877366,87622,403195,6110-1,066-3,2514,3160000
Accruals and Deferred Income-136,311105,777261,23458,342221,262-374,076-102,583613,51586,216000000
Deferred Taxes & Provisions000000000000000
Cash flow from operations163,878-719,200223,815-632,007486,113-362,854-81,690636,78675,23563930,2165067-45-1,250
Investing Activities
capital expenditure000000000000000
Change in Investments-1-5860524-287-1600608,082000000
cash flow from investments15860-5242871600-60-8,082000000
Financing Activities
Bank loans000000000000000
Group/Directors Accounts000000000000000
Other Short Term Loans 000000000000000
Long term loans000000000000000
Hire Purchase and Lease Commitments000000000000000
other long term liabilities-165,208-62,532164,56119,502692,1150000000000
share issue-16,521-1,36501,267,454-47-26010231075-51-66451,251
interest99,156109,233008893,5903,4871,044325154760000
cash flow from financing-82,57345,336164,5611,286,956692,9573,5643,4871,05434826181-51-66451,251
cash and cash equivalents
cash81,305-673,277388,376654,4241,179,357-359,129-78,202637,78067,50190130,2960000
overdraft000000000000000
change in cash81,305-673,277388,376654,4241,179,357-359,129-78,202637,78067,50190130,2960000

gemapharm limited Credit Report and Business Information

Very Low Risk70 - 100
Low Risk50 - 70
Moderate Risk30 - 50
High Risk20 - 30
Very High Risk0 - 20
Get a comprehensive credit check for gemapharm limited. Get real-time insights into gemapharm limited's credit score, group structure and payment trends.

From as little as £6.99

This will not impact your credit rating!

View Credit Report Sample

Gemapharm Limited Competitor Analysis

competitor_analysis_table_img

Perform a competitor analysis for gemapharm limited by selecting its closest rivals, whether from the WHOLESALE AND RETAIL TRADE; REPAIR OF MOTOR VEHICLES AND MOTORCYCLES sector, other mid companies, companies in BS8 area or any other competitors across 12 key performance metrics.

gemapharm limited Ownership

GEMAPHARM LIMITED group structure

Gemapharm Limited has no subsidiary companies.

Ultimate parent company

1 parent

GEMAPHARM LIMITED

03597444

GEMAPHARM LIMITED Shareholders

saville holdings ltd 90%
a-f sarl 10%

gemapharm limited directors

Gemapharm Limited currently has 4 directors. The longest serving directors include Mr Andrew Lamb (Dec 2013) and Mr Bernard Schack (Apr 2015).

officercountryagestartendrole
Mr Andrew Lamb74 years Dec 2013- Director
Mr Bernard SchackPortugal79 years Apr 2015- Director
Mr Hussain Al-TahanUnited Kingdom32 years Nov 2020- Director
Mr Romain ArnalUnited Kingdom46 years Apr 2024- Director

P&L

June 2024

turnover

9.3m

+47%

operating profit

821.6k

0%

gross margin

28.5%

+6.17%

turnover

Turnover, or revenue, is the amount of sales generated by a company within the financial year.

Balance Sheet

June 2024

net assets

2.5m

+0.38%

total assets

5.4m

+0.3%

cash

1.9m

+0.04%

net assets

Total assets minus all liabilities

gemapharm limited company details

company number

03597444

Type

Private limited with Share Capital

industry

46460 - Wholesale of pharmaceutical goods

incorporation date

July 1998

age

27

incorporated

UK

ultimate parent company

accounts

Total Exemption Full

last accounts submitted

June 2024

previous names

kenworld limited (April 2000)

seaway pharma limited (February 2000)

accountant

COLLINS JOHNSON CORPORATE SERVICES LTD

auditor

-

address

10 saville court saville place, clifton, bristol, BS8 4EJ

Bank

-

Legal Advisor

-

gemapharm limited Charges & Mortgages

A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.

We did not find charges/mortgages relating to gemapharm limited.

gemapharm limited Capital Raised & Share Issues BETA

When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.

Click to start generating capital raising & share issue transactions for GEMAPHARM LIMITED. This can take several minutes, an email will notify you when this has completed.

gemapharm limited Companies House Filings - See Documents

datedescriptionview/download